Chronomics, a healthtech company which allows individuals to track their health and wellbeing through epigenetic information, has received £1.12 million in seed funding after launching the company last year. The company’s aim is to change attitudes towards health management and help create a world where individuals can manage their own health.

The investment came from two leading venture capital companies, Anthemis and SOSV, the latter investing through the RebelBio programme after reviewing 350 companies. Other funding was secured from angel investors including Laurence Garrett, senior partner with Highland Europe.

CEO and founder Dr Tom Stubbs said of the news: “Reaching £1.12 million in seed funding is a momentous milestone for Chronomics, having just launched the company last year. Receiving the support of prominent backers reflects their confidence in our company, and our vision.”